Sartorius Stedim Biotech Stock EBITDA
| SDMHF Stock | USD 176.10 0.00 0.00% |
Sartorius Stedim Biotech fundamentals help investors to digest information that contributes to Sartorius Stedim's financial success or failures. It also enables traders to predict the movement of Sartorius Pink Sheet. The fundamental analysis module provides a way to measure Sartorius Stedim's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sartorius Stedim pink sheet.
Sartorius |
Sartorius Stedim Biotech Company EBITDA Analysis
Sartorius Stedim's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Sartorius Stedim EBITDA | 798.67 M |
Most of Sartorius Stedim's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sartorius Stedim Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Sartorius Stedim Biotech reported earnings before interest,tax, depreciation and amortization of 798.67 M. This is 8.98% lower than that of the Healthcare sector and 69.76% higher than that of the Medical Instruments & Supplies industry. The ebitda for all United States stocks is 79.51% higher than that of the company.
Sartorius EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sartorius Stedim's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sartorius Stedim could also be used in its relative valuation, which is a method of valuing Sartorius Stedim by comparing valuation metrics of similar companies.Sartorius Stedim is currently under evaluation in ebitda category among its peers.
Sartorius Fundamentals
| Return On Equity | 0.33 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 32.97 B | |||
| Shares Outstanding | 92.17 M | |||
| Shares Owned By Insiders | 73.81 % | |||
| Shares Owned By Institutions | 13.73 % | |||
| Price To Earning | 60.34 X | |||
| Price To Book | 13.58 X | |||
| Price To Sales | 9.62 X | |||
| Revenue | 2.89 B | |||
| Gross Profit | 1.55 B | |||
| EBITDA | 798.67 M | |||
| Net Income | 414.41 M | |||
| Cash And Equivalents | 161.7 M | |||
| Cash Per Share | 1.75 X | |||
| Total Debt | 521.07 M | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 24.67 X | |||
| Cash Flow From Operations | 695.97 M | |||
| Earnings Per Share | 7.94 X | |||
| Price To Earnings To Growth | 3.43 X | |||
| Number Of Employees | 10.41 K | |||
| Beta | 0.45 | |||
| Market Capitalization | 34.9 B | |||
| Total Asset | 3.95 B | |||
| Z Score | 39.6 | |||
| Annual Yield | 0 % | |||
| Five Year Return | 0.50 % | |||
| Net Asset | 3.95 B |
About Sartorius Stedim Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sartorius Stedim Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sartorius Stedim using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sartorius Stedim Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sartorius Pink Sheet
Sartorius Stedim financial ratios help investors to determine whether Sartorius Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.